Death

Safety-Focused E-scooter Provider Neuron Mobility Partners With Leading Canadian Road Safety Charity Traffic Injury Research Foundation (TIRF)

Goal, Partnership, Policy, Friends, Congestion, Health, Injury, Death, TIRF, Carbon, Heart, Travel, Industry, Neuron, Legislation, CEO, Program, City, GPS, Family, Technology, Mobility, Drinking, Research, Safety, Habit, Data collection, Noise, United Kingdom, Education, Traffic Injury Prevention, GLOBE, Car rental, Dietary supplement, Ridesharing company, Pharmaceutical industry, Road
Monday, September 27, 2021 - 7:10pm

Neuron Mobility and leading Canadian road safety charity, the Traffic Injury Research Foundation, partner to promote e-scooter safety across Canada

Key Points: 
  • Neuron Mobility and leading Canadian road safety charity, the Traffic Injury Research Foundation, partner to promote e-scooter safety across Canada
    The partnership includes input on Neurons rider education materials, co-development of safety campaigns, and analysis of Neurons safety data
    TIRF works with governments and stakeholders across Canada to make roads safer and reduce road deaths and injuries.
  • As part of the partnership, TIRF is collaborating with Neuron and co-developing campaigns and activities to promote rider safety in Canada.
  • Zachary Wang, CEO of Neuron Mobility, said: Safety is at the heart of everything we do at Neuron so we are delighted to partner with TIRF, the leaders in road safety research in Canada.
  • For more information, visit: https://www.rideneuron.com
    Traffic Injury Research Foundation (TIRF) is an independent, charitable road safety research institute.

Statement Regarding Dissemination of COVID-19 Misinformation

Intensive care unit, Federation, Self-assessment, FSMB, Patient, Evidence-based medicine, American Board of Obstetrics and Gynecology, ABMS, Death, OB, Physician, Revocation, American Board of Commissioners for Foreign Missions, CDC, GLOBE, Public health, Federation of State Medical Boards, ACOG, Obstetrics, Professional, COVID-19, American Board of Medical Specialties, Maintenance, Certificate policy, Infection, Learning, ABOG, Medical specialty, MOC, Pharmaceutical industry, Medicine
Monday, September 27, 2021 - 7:00pm

Additionally, ABOG supports a recent American Board of Medical Specialties (ABMS) statement , which expresses concern regarding the serious public health effects of the persistent spread of misinformation regarding the COVID-19 virus.

Key Points: 
  • Additionally, ABOG supports a recent American Board of Medical Specialties (ABMS) statement , which expresses concern regarding the serious public health effects of the persistent spread of misinformation regarding the COVID-19 virus.
  • Patients rely on physicians to practice evidence-based medicine based on facts and scientific data.
  • These standards include:
    Providing intentional misinformation that may harm patients or public health does not meet these standards and may be grounds for adverse action on OB GYN certification status.
  • In addition, ABOG is alerted if an OB GYN is investigated for practice or professionalism violations by a state medical board.

Zeus Electric Chassis, Inc. to be Featured in Mobility Product Showcase at E Source Forum 2021

Government, Adoption, Elohist, Partnership, Death, SMUD, Thought, Solution, EV, CMC, Class, Original equipment manufacturer, CO, Forum, Q&A, Industry, City, Sacramento Municipal Utility District, Technology, Mobility, Intelligence, Learning, Online shopping
Monday, September 27, 2021 - 5:45pm

Zeus Electric Chassis, Inc. (Zeus) is one of six innovators in the mobility industry invited to participate in a Mobility Product Showcase.

Key Points: 
  • Zeus Electric Chassis, Inc. (Zeus) is one of six innovators in the mobility industry invited to participate in a Mobility Product Showcase.
  • Bill Brandt, Zeus Chief Revenue Officer, will present a short video about Zeus Electric Chassis and participate in an open Q&A session.
  • In the case of Zeus, E Source will join the CMC and the Sacramento Municipal Utility District (SMUD) to independently evaluate Zeus product performance.
  • Learn more about E Source at www.esource.com, and learn more about the forum at www.web.cvent.com/event/5accf916-e3e5-4742-9a54-91628c39fdfe/summary .

Top health organizations urge flu and COVID-19 vaccines to protect vulnerable, reduce burden on hospitals

People, Degenerative disease, Korea Disease Control and Prevention Agency, American Heart Association, Vaccine, Canadian Lung Association, Charity Navigator, American Lung Association, Health, Volunteering, Cancer, Death, ADA, American Diabetes Association, Hospital, Chronic lung disease, CDC, Virus, Diabetes, American Heart, Lung cancer, COVID-19 vaccine, Disease, Life, Risk, Center, COVID-19, Pfizer, Pneumonia, Research, Education, Organization, Prediabetes, Quality of life, Connected for Life, Candid (organization), COVID-19 deaths, Vaccination, Pharmaceutical industry, Animal
Monday, September 27, 2021 - 5:21pm

According to the Centers for Disease Control and Prevention (CDC), the flu vaccine and the COVID-19 vaccines can be given in the same visit.

Key Points: 
  • According to the Centers for Disease Control and Prevention (CDC), the flu vaccine and the COVID-19 vaccines can be given in the same visit.
  • Both the flu vaccine and the COVID-19 vaccines are safe for people with chronic health conditions and are proven to provide the best protection against life-threatening complications from the two different viruses.
  • "We encourage everyone over six months old to get a flu shot and everyone over 12 years old get a COVID-19 vaccine.
  • "The flu is also significantly worse for people with diabetes and therefore, we strongly recommend getting both the flu and COVID-19 vaccines to protect your health if you are eligible.

Everside Health National Survey Shows Why More Than a Third of Americans Don't Plan to Get Flu Shot

Student, Probability, Bridgepoint Active Healthcare, Vaccine, Thought, Patient, Health, Multimedia, Death, Bellows Falls Co-operative Creamery Complex, The Harris Poll, Adult, Hospital, Virus, CDC, Workplace, COVID, Absenteeism, Centers for Disease Control and Prevention timeline, Risk, Center, COVID-19, View, Pharmaceutical industry, Health insurance, Fireworks, Online shopping
Monday, September 27, 2021 - 4:08pm

"Even if you already received a COVID vaccine you still need your flu shot."

Key Points: 
  • "Even if you already received a COVID vaccine you still need your flu shot."
  • "Even if you already received a COVID vaccine you still need your flu shot," said Dr. Tobias Barker, Everside Health Chief Medical Officer.
  • Everside commissioned a national survey out of concern that some people may not be getting flu shots due to misinformation and misunderstandings about the risks.
  • Married people are also more likely to plan to get a flu shot this year than unmarried people (70% vs. 59%).

Global Animal Nutrition Organic Acids (Poultry, Swine, Ruminants, Aqua) Market to 2028 by Product, Species, Application, Delivery System, Region - ResearchAndMarkets.com

Chemicals, Plastics, Health, Consumer, Manufacturing, Pets, Veterinary, Nature, Nutritional science, Animal, USD, PH, Gastrointestinal tract, CAGR, Bird, Miniature pig, Poultry, Aqua, Growth, Risk, Acid, Salt, GIT, Probiotic, Death, Feed manufacturing, Dietary supplement
Monday, September 27, 2021 - 2:53pm

The "Global Animal Nutrition Organic Acids Market 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Animal Nutrition Organic Acids Market 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global animal nutrition organic acids market size is expected to reach USD 187.1 million by 2028.
  • The market is expected to expand at a CAGR of 6.5% from 2021 to 2028.
  • Organic acids are being increasingly used for feed preservation in commercial compound feeds and applications related to diets in pigs and poultry.

DGAP-News: Nantes University Hospital Doses First Patients with Eckert & Ziegler's Novel Ga-68 Imaging Agent PENTIXAFOR

ISIN, European Association of Nuclear Medicine, Oncology, PET, European Medicines Agency, University Hospital (Newark, New Jersey), Deutsch, ISS, Multiple myeloma, Bone marrow, Centre Hospitalier Universitaire Grenoble Alpes, European Association for the Study of the Liver, CXCR4, III, News, Therapy, Cancer, Patient, Death, DGAP, Association, Nuclear medicine, TecDAX, FDG-PET, Lymphoma, Lymphatic system, Teaching hospital, Disease, B cell, FDG, CHU, Research, IRON, Society, Security (finance), Medical imaging, Pharmaceutical industry
Monday, September 27, 2021 - 2:19pm

The Centre Hospitalier Universitaire de Nantes (CHU), the French university hospital serving the greater Nantes/Saint-Nazaire metropolitan area, has started to dose first patients with PENTIXAFOR, an innovative imaging compound for the initial staging of cancer patients with symptomatic multiple myelomas.

Key Points: 
  • The Centre Hospitalier Universitaire de Nantes (CHU), the French university hospital serving the greater Nantes/Saint-Nazaire metropolitan area, has started to dose first patients with PENTIXAFOR, an innovative imaging compound for the initial staging of cancer patients with symptomatic multiple myelomas.
  • To investigate the potential of PENTIXAFOR the CHU will recruit, on its own account, up to 45 patients in a so-called investigator-initiated study (ISS).
  • Given the potential of PENTIXAFOR for improved patient stratification, academic groups like CHU have decided to move ahead on their own and to test PENTIXAFOR right away.
  • To speed up the PENTIXAFOR marketing authorization, Eckert & Ziegler closely cooperates with such initiatives and supports them where feasible.

Sarepta Therapeutics to Initiate Part B of MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions with FDA

Neck, Goal, Therapy, Review, Arthralgia, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Muscular dystrophy, Degenerative disease, Death, Dystrophin, Safety, Mutation, SEC, Food, Upper respiratory tract infection, PMO, LinkedIn, Part, United States Patent and Trademark Office, Twitter, Male, Breathe Me, Hypotension, Sarepta, Magnesium, Incidence, SRPT, Bronchospasm, Patent, Vomiting, U.S. Securities and Exchange Commission, RNA transfection, Duchenne muscular dystrophy, RNA, Skin, Annual report, Sale, NASDAQ, Sarepta Therapeutics, FDA, Company, Rash, Hives, Flushing, Bruise, GLOBE, Investor Protection and Securities Reform Act of 2010, Gene editing, Instagram, Risk, Patient, Cough, Chemistry, DMD, Balance disorder, COVID-19, Pharmaceutical industry, Vaccine, Dentistry
Monday, September 27, 2021 - 1:30pm

CAMBRIDGE, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that following positive interactions with the U.S. Food and Drug Administration (FDA), the Company plans to initiate Part B of the MOMENTUM study (Study 5051-201), in the fourth quarter. MOMENTUM is a global trial investigating the use of SRP-5051, the Company’s next-generation peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) to treat patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping.

Key Points: 
  • MOMENTUM is a global trial investigating the use of SRP-5051, the Companys next-generation peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) to treat patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping.
  • The study will enroll between 20-40 patients between ages 7 to 21 amenable to exon 51 skipping who are nave to SRP-5051.
  • SRP-5051 is designed to bind to exon 51 of dystrophin pre-mRNA, resulting in exclusion of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping.
  • EXONDYS 51 is indicated for the treatment of Duchenne muscular dystrophy in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping.

StoneMor Inc. Announces Receipt of Letter Inviting Discussions Regarding Strategic Alternatives

Letter, Risk, Security (finance), Private Securities Litigation Reform Act, Axar Patel, U.S. Securities and Exchange Commission, Board, Cemetery, Funeral, GLOBE, Death, Company, Forward-looking statement, NYSE, Time, Audit
Monday, September 27, 2021 - 1:45pm

Axar has engaged Schulte Roth & Zabel LLP as its legal advisor and stated in the Letter that it would engage a financial advisor at the appropriate time.

Key Points: 
  • Axar has engaged Schulte Roth & Zabel LLP as its legal advisor and stated in the Letter that it would engage a financial advisor at the appropriate time.
  • According to the Letter, Axar expects that any such discussions would be conducted with a special committee of the Board, assisted by financial and legal advisors it engages.
  • The Conflicts Committee intends to retain independent legal and financial advisors to assist in such discussions.
  • Certain statements contained in this press release, including, but not limited to, information regarding actions of the Conflicts Committee, are forward-looking statements.

Acasti Pharma Announces Initiation of Pharmacokinetic Bridging Study for GTX-104, the Company’s Lead Drug Candidate for the Treatment of Subarachnoid Hemorrhage

ACST, Securities Act of 1933, Review, Death, Stroke, Micelle, Bleeding, Safety, Calendar, Blood pressure, Subarachnoid hemorrhage, Compliance, Drug Quality and Security Act, CRU, IV, Central nervous system, SubArachnoid Space, Private Securities Litigation Reform Act, Disability, BA, SAH, Capsule, Incidence, Brain, Orphan, Aneurysm, Water, NASDAQ, U.S. Securities and Exchange Commission, FDA, Nimodipine, Experimental cancer treatment, A-T, Marketing, Acquisition, Company, Vital signs, DCI, GLOBE, PHN, Grace, PK, Risk, TSX, Security (finance), Skull, Postherpetic neuralgia, Patient, Nerve Damage, Rupture, COVID-19, Securities Exchange Act of 1934, Neuropathic pain, Blood, ASAH, Cryptocurrency, Pharmaceutical industry, Medical imaging
Monday, September 27, 2021 - 1:30pm

This latest study follows an earlier safety and dose-escalation crossover study conducted by Grace, which reported encouraging results.

Key Points: 
  • This latest study follows an earlier safety and dose-escalation crossover study conducted by Grace, which reported encouraging results.
  • Moreover, it could provide a more convenient dosing schedule that would be easier to administer to patients who are unconscious.
  • The PK bridging study is a single center, randomized, two-period crossover study in 50 healthy subjects.
  • Acasti is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases.